

BZ FINE PHARMA



Factsheet October 2024

Fund data

| | |
|---------------------------------|--------|
| Price on October 31, 2024 (CHF) | 246.94 |
| High last 12 months (CHF) | 262.13 |
| Low last 12 months (CHF) | 209.47 |
| Fund volume (CHF mn) | 47.51 |
| Volatility over last year | 11.9% |
| Performance since inception | 146.9% |

Performance (in %)

| | Oct 2024 | 1 year | 2023 | 2022 | 2021 | 2020 |
|-------|----------|--------|------|-------|---------|------|
| CHF A | -0.3 | 17.9 | -7.2 | -17.9 | 4.25447 | 10.1 |
| EUR A | -0.3 | 32.1 | -1.3 | -13.6 | 8.96831 | 10.8 |
| EUR T | -0.3 | 19.9 | -1.5 | -13.6 | 8.96033 | 10.7 |

Performance was calculated on the basis of net asset values (NAV).

General information

| | |
|---------------------------|------------------------------------------------------------------------|
| Inception | January 15, 2013 |
| All-in-fee | depends on unit class (see Sales prospectus) |
| Issuance / redemption fee | max. 2% |
| Issuances / redemptions | daily |
| ISIN / Valor-Number | |
| Share class CHF A | LU0695504364 / 141'427'05 |
| Share class EUR A | LU0695506492 / 141'428'14 |
| Share class EUR T | LU0695508431 / 141'425'15 |
| Share class CHF AV | LU1077079306 / 247'874'44 |
| Bloomberg | BZPHAAF LX |
| Reuters | BZBANK |
| Domicile | Luxembourg |
| Legal structure | SICAV, UCITS |
| Custodian bank | DZ Privatbank S.A. |
| Fund administrator | IPConcept (Luxemburg) S. A. |
| Subscriptions | All banks |
| Fund manager | BZ Bank Aktiengesellschaft |
| Registered in | AUT, CH, DE, LUX |
| Representative AUT | Erste Bank der oest. Sparkassen AG |
| Representative CH | IPConcept (Schweiz) AG |
| Representative DE | DZ Bank AG |
| Paying agent | DZ Privatbank S.A. |
| Paying agent CH | BZ Bank Aktiengesellschaft |
| Contact | BZ Bank Aktiengesellschaft |
| | Egglirain 15 |
| | 8832 Wilen |
| | Tel +41 44 786 66 00 |
| | peter.rebsamen@bzbank.ch |

Fund description

The objective of the investment policy of the BZ Fine Funds – BZ Fine Pharma (“sub-fund”) is to achieve appropriate growth in the specific currency of the share class while taking investment risk into consideration. The return yield of the sub-fund must not only preserve the whole of the invested capital but also be at least equal to inflation and produce an attractive actual return. The return should considerably exceed that of fixed-interest and real-estate investments. This sub-fund seeks to benefit from recognized trends in the healthcare sector in the emerging markets as well as the developed nations. Therefore, the investment universe is not limited to a specific geographic region. This sub-fund invests its assets in healthcare companies, such as pharmaceuticals, biotechnology, equipment and services, medical technology, specialist pharmaceuticals and generic products. The investment decisions are based on the fundamental assessment of the companies and not on their market capitalisation or location.

Monthly performance (in %)¹


Net asset value (NAV) since January 15, 2013, Share class CHF A



Source: Macrobond

Portfolio structure by sector

(In % of total assets)



Risk profile of the Fund

The Fund is appropriate for growth-oriented investors. Due to the composition of the sub-fund assets, there is a high degree of risk but also a high degree of profit potential. The principal risks of the Fund lie in the concentration of the assets in a specific sector. Compared with the financial market for all sectors, bigger differences in market movements and developments may occur in the short and medium term compared with a specific sector of industry, whether due to a different stage in an economic cycle or to sector-specific or political circumstances. There is no guarantee that the investor will achieve a specific income or that the units will be redeemed at a specific price.

DISCLAIMER: Die Informationen auf diesem Factsheet gelten nicht als Offerte. Sie dienen nur zu Informationszwecken. Die vergangene Performance ist keine Garantie für zukünftige Entwicklungen. Alleine Grundlage für den Kauf von Aktien sind die Verkaufsunterlagen (der aktuelle Verkaufsprospekt, die Basisinformationsblätter, die Satzung sowie die Berichte). Eine aktuelle Version der Verkaufsunterlagen erhalten Sie kostenlos bei den genannten Informationsstellen.

¹ Hinweise auf die vergangene Wertentwicklung sind kein Indikator für künftige Ergebnisse und garantieren nicht notwendigerweise positive Entwicklungen in der Zukunft. Die Performancedaten beinhalten nicht die Kommissionen und Kosten bei der Ausgabe und Rücknahme der Anteile. Hinweise zu Chancen und Risiken entnehmen Sie bitte dem aktuellen ausführlichen Verkaufsprospekt.